

Opyl Ltd

14:48 19 Feb 2020

Opyl develops AI-based software to predict success and pitfalls in clinical studies

Opyl Ltd (ASX:OPL) has completed the first critical proof-of-concept stage of development of a machine learning, artificial intelligence-based software interface which can predict the likelihood of a clinical trial completing each phase.

The software works to optimise clinical trials across areas such as study planning, protocol design, recruitment and site location through to selection of the best CRO (contract research organisation) for particular diseases in key geographic locations based on their historical performance.

The Opyl technology is based on information from in excess of 300,000 published trials and more than 60 trial variables across a wide selection of diseases and conditions.

The application of an emerging branch of data science, 'explainable AI', has been used to develop the algorithm.

Reduces risk to global biopharma developers
Chief executive officer Michelle Gallaher said: "The Opyl algorithm has the potential to dramatically disrupt the clinical trial feasibility sector, reducing risk and cost to global biopharma and medtech developers.

"This technology has the potential to create more certainty in the typically risky clinical trial stage, which in turn means success worth millions if not billions to a biopharma or medtech company.

"The program has demonstrated its potential impact on specific variables on trial success such as the choice of CRO, site (hospital), academic partners and dosing strategy.

"Understanding how trial variables impact on outcome is a powerful competitive advantage for developers in designing the optimal protocol and for investors looking to reduce risk and optimise returns."

Model to attract fund managers and investors

The Opyl model has estimated some trials as having up to a 70% chance of success, while other trials are as low as less than 1% and the technology represents a major milestone for the company as it pursues a new strategic direction in digital health.

While the primary market for the clinical trial predictor tool will be typically major biopharma and medtech developers who invest in large numbers of trials each year and seek to reduce risk, fund managers and investors will likely have a strong interest in predicting the likely success of their investments.

Gallaher continued: "We can work with all companies undertaking clinical studies across medical devices, pharmaceuticals, biologics and diagnostics to help them predict the outcome of their studies as well as improve the execution of the clinical trial through site selection, trial protocols and CRO choice."

Price: 0.145

Market Cap: \$4.29 m

1 Year Share Price Graph



Share Information

Code: OPL

Listing: ASX

| | | |
|----------------|-------------|-------------|
| 52 week | High | Low |
| | 0.19 | 0.04 |

Sector: Online business & e-commerce

Website: opyl.ai

Company Synopsis:

Opyl (ASX:OPL) is a new generation company working at the intersection of artificial intelligence, social media and clinical trials.

action@proactiveinvestors.com.au

The tool could also give smaller developers confidence in their trial designs and may use the predictive approach to build confidence, attracting further investment and commercial partners.

Expected launch in September quarter

It is expected the Opyl model will be commercialised on a subscription basis, with additional bespoke consulting services most likely aimed at pharmaceutical, biotechnology, government, hospitals, universities and research institutes, medical device companies, CRO's and investment houses.

The company is in preliminary discussion with several organisations in this space.

Accelerating the development of the Opyl algorithm is a key priority for the company with the vast majority of the research and development budget earmarked for the next two quarters being applied to its progression toward an expected market launch in the September quarter of 2020.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).